ArticleArchives of medical science : AMS2016
Chromogranin A - unspecific neuroendocrine marker. Clinical utility and potential diagnostic pitfalls.
Article in Archives of medical science : AMS, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 73 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
73 citing papers in PubMed, 138 citations in OpenAlex.
- NETest2.0Cancers · 2026Article
- The therapeutic potential of zinc-nanoparticles against the cerebellar neurotoxicity induced by bacterial lipopolysaccharides in female rats and their pups.Scientific reports · 2026Article
- When an Adrenal Mass Isn't Cancer: A Rare Case ofJCEM case reports · 2026Article
- Candidate proteomic indirect-effect signals linking dementia to probable muscle-bone fragility: a UK Biobank cohort study.Frontiers in medicine · 2026Article
- Expression of ubiquitin carboxyl-terminal hydrolase isozyme L1 and chromogranin A regulated via histone-modification through Rho/ERK/NFκB signaling in oxaliplatin-resistant colorectal cancer cells.International journal of medical sciences · 2026Article
- Complications and outcomes of radioligand therapy in patients with neuroendocrine neoplasms depending on the baseline glomerular filtration rate.European journal of nuclear medicine and molecular imaging · 2025Article
- Elevated Serum Chromogranin-A and Characteristic Duodenal Enteroendocrine Cell Distribution in Pancreatic Fibrosis and Chronic Pancreatitis Compared with Other Dyspeptic Disorders: A Case Series Study.Diagnostics (Basel, Switzerland) · 2025Article
- Diagnostic role of endoscopic ultrasonography in defining the clinical features and histopathological spectrum of gastroenteropancreatic neuroendocrine tumors.World journal of gastrointestinal endoscopy · 2025Article
- Sweat gland carcinoma with neuroendocrine differentiation of the scalp with elevated serum chromogranin A levels.JAAD case reports · 2025Article
- Allelic expression patterns of imprinted and non-imprinted genes in cancer cell lines from multiple histologies.Clinical epigenetics · 2025Article
- Elevated serum chromogranin A levels are independently associated with metabolic and inflammatory disturbances in polycystic ovary syndrome.Frontiers in endocrinology · 2025Article
- Article
- Adenocarcinoma admixed with neuroendocrine carcinoma of the cervix: A case report and review of literature.Case reports in women's health · 2024Article
- Small Intestinal Xanthomatosis Mimicking Neuroendocrine Tumor.ACG case reports journal · 2024Article
- Rare presence and function of neuroendocrine cells in the nasal mucosa.Frontiers in immunology · 2024Article
- Two cases of pancreatic tuberculosis in immunocompetent individuals presenting as diabetes mellitus: An overview of clinical features, diagnosis and management.Qatar medical journal · 2024Article
- Single-Time-Point Imaging for Dosimetry After [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2023Article
- Current Biomarkers for Carotid Artery Stenosis: A Comprehensive Review of the Literature.Metabolites · 2023Review
- Defining triple-negative breast cancer with neuroendocrine differentiation (TNBC-NED).The journal of pathology. Clinical research · 2023Article
- Chromogranin A: An Endocrine Factor of Pregnancy.International journal of molecular sciences · 2023Review
13 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chromogranin A, despite a number of limitations, is still the most valuable marker of neuroendocrine tumors (NETs). Granins belong to the family of acidic proteins that constitute a major component of secretory granules of various endocrine and neuroendocrine cells, which are components of both the classical endocrine glands and the diffuse neuroendocrine system. These cells are a potential source of transformation into neuroendocrine tumors. The awareness of potential causes influencing the false results of its concentrations simplifies diagnosis and treatment. One of the disadvantages of this marker is its non-specificity and the existence of a number of pathological processes leading to an increase in its concentration, which often results in confusion and diagnostic difficulties. The molecular structure is characterized by a number of sites susceptible to the proteolytic activity of enzymes, resulting in the formation of a number of biologically active peptides. Presumably they act as precursors of active proteins. Chromogranin expression correlates with the amount of secretory vesicles in neuroendocrine cells. The peptide chain during biochemical changes becomes a precursor of biologically active proteins with a wide range of activities. There are a number of commercially available kits for the determination of chromogranin A, which differ in methodology. We present the evaluation of chromogranin A as a marker of neuroendocrine tumors in clinical practice and the possible factors that may affect the outcome of its concentration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.